Don’t Miss TipRanks’ Half-Year Sale
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
Jiangsu Hengrui Pharmaceuticals Co., Ltd. Class H ( (HK:1276) ) has provided an update.
Jiangsu Hengrui Pharmaceuticals Co., Ltd. has announced that its subsidiary, Suzhou Suncadia Biopharmaceuticals Co., Ltd., received conditional approval from the National Medical Products Administration for its self-developed Class 1 innovative drug, Trastuzumab Rezetecan for Injection. This drug is intended for the treatment of adult patients with HER2-mutant non-small cell lung cancer who have previously undergone systemic therapy. This approval marks a significant milestone as it is the first self-developed antibody drug conjugate in China approved for this patient group, potentially enhancing the company’s position in the oncology sector and offering new treatment options for patients.
More about Jiangsu Hengrui Pharmaceuticals Co., Ltd. Class H
Jiangsu Hengrui Pharmaceuticals Co., Ltd. is a leading pharmaceutical company based in China, specializing in the development and manufacturing of innovative drugs, particularly in the field of oncology. The company focuses on creating therapeutic biological products and has a strong presence in the Chinese pharmaceutical market.
Average Trading Volume: 27,396,529
Current Market Cap: HK$369.6B
See more insights into 1276 stock on TipRanks’ Stock Analysis page.